[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"trial:NCT01890486":3,"trial-entities:NCT01890486":79,"trial-summary:NCT01890486":92},{"id":4,"nct_id":4,"org_study_id":5,"brief_title":6,"official_title":7,"overall_status":8,"completion_date":9,"status_verified_date":10,"last_update_date":11,"start_date":12,"sponsor_name":13,"lead_sponsor_class":14,"has_dmc":15,"brief_summary":16,"detailed_description":17,"conditions":18,"keywords":29,"study_type":30,"primary_purpose":31,"phases":32,"enrollment_info":33,"interventions":36,"primary_outcomes":37,"secondary_outcomes":42,"sex":43,"minimum_age":44,"maximum_age":45,"healthy_volunteers":15,"eligibility_criteria":46,"std_ages":50,"locations":53,"central_contacts":71,"overall_officials":75,"references":77,"see_also_links":78},"NCT01890486","CCCWFU 95300","The Prospective Collection, Storage and Reporting of Data on Patients Undergoing Hematopoietic Stem Cell Transplantation Utilizing a Standard Preparative Regimen","The Prospective Collection, Storage and Reporting of Data on Patients","RECRUITING","2026-12","2026-04","2026-04-13","2001-05-21","Wake Forest University Health Sciences","OTHER",false,"To provide the IRB approved mechanism for the prospective collection and analysis on participants who are undergoing either an autologous or allogeneic hematopoietic stem cell transplant for a disease in which a research question is not being addressed.","To provide an IRB approved mechanism for the prospective collection and analysis on participants who are undergoing either an autologous or allogeneic hematopoietic stem cell transplant or cellular therapies for a disease in which a research question is not being addressed and for which peer reviewed, published data have demonstrated efficacy for this treatment approach.\n\nTo provide a consent mechanism for the retrospective study of cellular products, when available, if there is a specific question to be addressed.",[19,20,21,22,23,24,25,26,27,28],"Acute Myelogenous Leukemia","Acute Lymphocytic Leukemia","Chronic Myelogenous Leukemia","Non-Hodgkin's Lymphoma","Hodgkin's Disease","Multiple Myeloma","Germ Cell Neoplasms","Myelodysplastic Syndromes","Chronic Lymphocytic Leukemia","Immunodeficiency Diseases",[],"OBSERVATIONAL",null,[],{"count":34,"type":35},2000,"ESTIMATED",[],[38],{"measure":39,"description":40,"timeFrame":41},"Data followup","Gather basic survival and complication data for operational and research databases for ongoing regulatory and future operational queries","1 year",[],"ALL","18 Years","120 Years",{"inclusion":47,"exclusion":48,"raw_text":49},[],[],"Inclusion Criteria:\n\nPlanned standard of care dose intensive therapy and either an allogeneic or autologous bone marrow transplant\n\nExclusion Criteria:\n\nParticipation in any other treatment research protocol",[51,52],"ADULT","OLDER_ADULT",[54],{"facility":55,"status":8,"city":56,"state":57,"zip":58,"country":59,"contacts":60,"geoPoint":68},"Wake Forest Baptist Health","Winston-Salem","North Carolina","27157","United States",[61,66],{"name":62,"role":63,"phone":64,"email":65},"David Hurd, MD","CONTACT","336-716-2843","dhurd@wakehealth.edu",{"name":62,"role":67},"PRINCIPAL_INVESTIGATOR",{"lat":69,"lon":70},36.09986,-80.24422,[72],{"name":73,"role":63,"email":74},"Dianna Howard, MD","dhoward@wakehealth.edu",[76],{"name":73,"affiliation":13,"role":67},[],[],{"nct_id":4,"conditions":80,"biomarkers":91},[81,82,27,83,84,85,86,87,24,88,89,90],"Acute Lymphoblastic Leukemia","Acute Myeloid Leukemia","Chronic Myeloid Leukemia, BCR-ABL1 Positive","Germ Cell Tumor","Hematologic Neoplasm","Hodgkin's Granuloma","Immunodeficiency","Myelodysplastic Syndrome","Non-Hodgkin Lymphoma","Solid Neoplasm",[],{"nct_id":4,"found":93,"summary":94,"prompt_version":104},true,{"design":95,"status":96,"heading":97,"summary":98,"follow_up":99,"word_count":100,"commitments":101,"compensation":102,"drugs_mentioned":103},"This is an observational study, meaning it collects information without testing a specific intervention. It aims to include up to 2000 participants.","completed","Observational Study of Hematopoietic Stem Cell Transplantation","This study is collecting information from people undergoing a standard hematopoietic stem cell transplant (a procedure that replaces damaged blood-forming cells with healthy ones). It's for individuals with certain blood cancers like Acute Myelogenous Leukemia or Non-Hodgkin's Lymphoma. The study isn't testing a new treatment, but rather observing the outcomes of standard care. We are looking for up to 2000 participants aged 18 to 120 years old who are planning to have either an allogeneic (from a donor) or autologous (using your own cells) bone marrow transplant. The main goal is to collect and analyze data for one year after your transplant to understand how well these standard treatments work.","Your data will be followed up for one year after the transplant.",110,"Not specified in the trial record.","Not stated in the trial record.",[],"v2"]